In this heterogeneous genomic scenario and in the era of precision medicine, despite the low prevalence of its genetic alterations, HER2 is emerging both as a key driver in CRC, as well as a predictor of benefits from novel targeted therapies [47]. The gene discussed is ERBB2; the disease is colorectal carcinoma.